ELOBP4

Across TCGA pan-cancer cohorts, ELOBP4 RNA is linked to patient survival in 13 of 34 cancer types, making it the most broadly survival-associated ELOBP4 data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher ELOBP4 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated ELOBP4 expression acts as an unfavorable survival marker, although some lineages such as ESCA and LAML show a favorable association.

LIHC, LUSC, and KIRP are the cancer types where ELOBP4 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Tertile	All	0.178	0.446	.001	54	view →
LUSC	OS	Tertile	IV	0.001	0.673	.014	36	view →
KIRP	OS	Tertile	II,III,IV	0.141	0.673	.017	18	view →
ESCA	OS	Quartile	II,III,IV	0.628	0.404	.023	15	view →
READ	DFS	Tertile	III,IV	0.446	0.774	.006	15	view →
KIRC	DFS	Tertile	IV	0.167	0.401	.023	12	view →
PRAD	OS	Tertile	All	0.977	0.996	.017	12	view →
BLCA	DFS	Tertile	IV	0.268	0.503	.007	9	view →
GBM	DFS	Tertile	All	0.111	0.251	.013	9	view →
PCPG	DFS	Tertile	All	0.063	0.921	<.001	9	view →
LAML	DFS	Tertile	All	0.493	0.310	.037	8	view →
MESO	OS	Tertile	All	1.000	0.261	.046	3	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 13 lineages.

ELOBP4–LIHC (DFS)

Open the LIHC breakdown →